EMJ Hematology 10 [Supplement 1] . 2022

Journal Info

Multiple myeloma (MM) is an incurable disease and is the second most common haematologic malignancy in the world. Over the past decade, therapies for MM have improved their safety profile and efficacy. However, patients with MM eventually stop responding to treatment and relapses are very common. Isatuximab (Isa), a monoclonal antibody, is approved to treat relapsed/refractory (RR) MM in combination with either pomalidomide (P) and dexamethasone (d) or carfilzomib (K) and d.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?